Positive Updates Announced for Inhaled Voriconazole and Tacrolimus Programs;
Both Programs Advancing into Phase 2 Testing
Continued Progress with Partnered Antiviral Programs for AUG-3387 and Niclosamide
Thin Film Freezing Applications Continue to Expand Across Diverse Set of Drug Candidates; IP Estate Now Includes Over 120 Patents Granted or Pending
Conference Call and Webcast Scheduled Today,
at
“Over the last three months, we have made significant progress in every aspect of our business,” said
“Results from our Phase 1 study for Inhaled Tacrolimus Powder indicate that our inhaled product has an acceptable safety profile to achieve the appropriate balance of local and systemic concentrations for immunosuppression at the site of the lung transplant while minimizing the risk of supra-therapeutic exposure well known to cause significant renal toxicity in patients. Based on the data, we expect to initiate the Phase 2 program shortly.”
“We are also making outstanding progress in our two antiviral-focused partnerships, which provided yet another major source of external validation showing how our Thin Film Freezing technology can be applied to both small molecules and biologics. In October,
“From our perspective, momentum only continues to build across the breadth of our diverse portfolio. The progress we have made and expect to make moves our entire internal portfolio closer to monetization and meaningful revenue streams for TFF.”
“Looking ahead, we believe 2022 is shaping up to be another year of significant accomplishments. As our clinical programs with inhaled tacrolimus and voriconazole continue to advance, we expect to generate substantial proof-of-concept data within each program’s targeted patient populations. Both the Inhaled Voriconazole and Inhaled Tacrolimus Powder Phase 2 programs will be designed with an interim analysis of data, and we expect these datasets will be available by mid-2022. We will begin a process in the first quarter of 2022 to identify license partners to ultimately commercialize these assets. We have already received interest from pharmaceutical companies and will use the interim data as the inflection point to pursue the partnerships.”
“Importantly, the applicability of Thin Film Freezing in creating successful formulations in biologics and complex molecules continues to grow. For example, we have recently seen a strong uptick in the number of mAbs and mRNA-based therapeutics being evaluated by our large pharma partners, and we expect this trend will continue. The applicability of our Thin Film Freezing technology across a broad array of different molecules has also enabled us to greatly expand our IP estate. TFF now has approximately 120 patents either granted or pending both in
“Without question, another important source of expanding applications of Thin Film Freezing comes from our academic and government collaborations, and I am pleased to report that each of these highly valued partnerships are proceeding very well. Our work with Dr.
“We have also made substantial progress with the Defense Advanced Research Projects Agency (DARPA) Personalized Protective Biosystem (PPB) contract on formulating countermeasures and the development of novel vaccines at the
“On the partnering front, the number of drug candidates being evaluated by our partners continues to grow and, just as importantly, we are seeing an expansion in the diversity of molecules being tested with our Thin Film Freezing technology. We expect to sign meaningful partnering transactions in the very near future. It is abundantly clear that the interest from our pharmaceutical, academic and government partners in our platform formulation technology continues to grow, and we are highly confident this interest will create multiple pathways toward increasing shareholder value.”
Conference Call and Webcast Information
The Company will host a conference call today,
Domestic Dial-In Number – Toll-Free: (866) 269-4261
International Dial-In Number: (323) 289-6581
Conference ID: 6229028
The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/46954/indexl.html
Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors section.
Recent Clinical and Corporate Highlights:
- Voriconazole Inhalation Powder (TFF VORI): In November, TFF announced the completion of dosing in the Phase 1b clinical trial of Voriconazole Inhalation Powder (TFF VORI), a next-generation, direct-to-lung, inhaled dry powder version of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA) (NCT #04576325). This study assessed the safety and tolerability of patients with mild to moderate asthma, a population at high risk of developing IPA, in two cohorts of eight patients. Initial data from the study suggests that TFF VORI is well tolerated in asthma patients, supporting the Company’s progress to a Phase 2 study in IPA patients.
The observational data from the Phase 1b trial indicates that TFF VORI is well tolerated in asthma patients. Voriconazole is recommended as the first line treatment for IPA according to the Infectious Disease Society (IDSA) – Practice Guidelines for the Diagnosis and Management of Aspergillosis (2016), but oral voriconazole is associated with significant drug-drug interactions and toxicities. Delivery of voriconazole directly to the lung may allow for a product that has greater efficacy than orally administered voriconazole and that has improved safety through reduced systemic toxicities and reduced drug-drug interactions.
To date, observational data from this trial support the inclusion of patients that have hyperreactive airway disease comorbidities in the Phase 2 trial. This suggests TFF VORI also may have the potential to treat Allergic Bronchopulmonary Aspergillosis (ABPA), which impacts up to 2.5%1 of asthma patients.
- Tacrolimus Inhalation Powder (TFF TAC): In September, TFF announced topline results from the recently completed Phase 1 clinical trial for Tacrolimus Inhalation Powder showing a promising safety profile and demonstrating therapeutic drug levels can be achieved at low doses.
Topline pharmacokinetic data from the Phase 1 study included:
• In the SAD phase of the study, inhaled delivery of tacrolimus resulted in mean trough blood levels of 10 ng/mL 12 hours post-dosing for subjects that received a dose of 5 mg, which falls within the desired range for maintenance immunosuppression following lung transplant.
• As previously reported in July, subjects from the MAD phase of the study who received doses of 0.5 mg twice daily and 1.0 mg twice daily achieved 12-hour trough steady state blood levels of tacrolimus that averaged 6.8 and 14.9 ng/mL, respectively, demonstrating that Inhaled Tacrolimus Powder can achieve blood levels generally deemed to be sufficient for efficacious immunosuppression.
• New data reported today showed that once daily dosing with 1.5 mg of Inhaled Tacrolimus Powder resulted in mean 12-hour trough blood levels of 6.3 ng/mL and mean 24-hour trough blood levels of 4.8 ng/mL, consistent with the desired therapeutic ranges for lung transplant patients.
TFF Pharmaceuticals expects to take critical steps toward beginning its Phase 2 clinical study of Inhaled Tacrolimus Powder by the end of 2021. The goal of the Phase 2 study, which will be an open-label study conducted in lung transplant patients who are experiencing kidney toxicity, is to test the hypothesis that Inhaled Tacrolimus Powder can provide adequate systemic exposure while maintaining higher drug levels in the lung, thereby reducing the risk of acute allograft rejection and improving symptoms of renal toxicity. We intend for patients currently receiving oral tacrolimus to transition to a flexible dosing regimen of inhaled tacrolimus. We expect the inhalation dose will be able to be adjusted weekly to achieve the desired blood level assigned by each patient’s physician and ongoing biomarker-based assessments.
Scientific Advisory Board (SAB): OnNovember 1 , TFF Pharmaceuticals held a first meeting with its Scientific Advisory Board, comprised of globally-recognized thought leaders in their respective fields of study. The SAB will advise TFF Pharmaceuticals across a range of issues, including internally developed programs and select external projects.- Strategic Business Development and Partnership Activities – Biopharmaceutical Companies and Research Institutions:
- In October, TFF announced approval from Health Canada to begin a Phase 1 clinical trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other infectious diseases. The Phase 1 study was cleared by Health Canada via a No Objection Letter (NOL) received on October 22, 2021. TFF Pharmaceuticals enrolled and dosed the first patient in the study today; enrollment is expected to be completed by early Q1 2022.
- In October, TFF and Augmenta Bioworks announced the publication of a research paper highlighting positive preclinical study results of AUG-3387, a monoclonal antibody (mAb) therapy being developed in collaboration between the two companies for the treatment of SARS-CoV-2 infection. The findings have been published online through the bioRxiv preprint server, under the title “AUG-3387, a Human-Derived Monoclonal Antibody Neutralizes SARS-CoV-2 Variants and Reduces Viral Load from Therapeutic Treatment of Hamsters In Vivo.”
- In July, TFF and Augmenta published positive in vitro data indicating that AUG-3387 binds to and neutralizes the SARS-CoV-2 Delta variant (B.1.617.2). The Delta variant is the current dominant strain of SARS-CoV-2 in the U.S., Europe and other geographic regions around the world.
Financial Results
For the three months ended
- Research and Development (R&D) expenses: R&D expenses for the third quarter of 2021 were
$6.3 million , compared to$2.8 million for the same period in 2020.
- General & Administrative (G&A) expenses: G&A expenses for the third quarter of 2021 were
$2.4 million , compared to$2.3 million for the same period of 2020. - Net Loss:
TFF Pharmaceuticals reported a net loss for the third quarter of 2021 of$8.7 million , compared to a net loss of$5.1 million for the same period of 2020.
About TFF Pharmaceuticals’ Thin Film Freezing Technology Platform
TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.
About TFF Pharmaceuticals
SAFE HARBOR
This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company’s TFF platform and its dry powder versions of Voriconazole and Tacrolimus, and the Company’s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its dry powder versions of Voriconazole and Tacrolimus, (ii) the risk that the Company may not be able to find a license partner to ultimately commercialize its dry powder versions of Voriconazole and Tacrolimus on terms favorable to the Company, or at all, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (v) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s 2020 Annual Report on Form 10-K filed with the SEC on March 10, 2021. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| Three Months Ended 2021 |
Three Months Ended 2020 |
Nine Months Ended 2021 |
Nine Months Ended 2020 |
||||||||||||
| Grant revenue | $ | 50,000 | $ | — | $ | 76,165 | $ | — | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 6,339,993 | 2,823,669 | 14,380,415 | 7,626,982 | |||||||||||
| General and administrative | 2,387,585 | 2,254,912 | 7,386,007 | 5,147,639 | |||||||||||
| Total operating expenses | 8,727,578 | 5,078,581 | 21,766,422 | 12,774,621 | |||||||||||
| Loss from operations | (8,677,578 | ) | (5,078,581 | ) | (21,690,257 | ) | (12,774,621 | ) | |||||||
| Other income: | |||||||||||||||
| Other income (expense) | (13,129 | ) | — | 659,695 | — | ||||||||||
| Interest income | 12,051 | 20,546 | 41,619 | 102,809 | |||||||||||
| Total other income (expense) | (1,078 | ) | 20,546 | 701,314 | 102,809 | ||||||||||
| Net loss | $ | (8,678,656 | ) | $ | (5,058,035 | ) | $ | (20,988,943 | ) | $ | (12,671,812 | ) | |||
| Net loss per share, basic and diluted | $ | (0.34 | ) | $ | (0.24 | ) | $ | (0.85 | ) | $ | (0.61 | ) | |||
| Weighted average common shares outstanding, basic and diluted | 25,371,781 | 20,867,526 | 24,635,350 | 20,810,004 | |||||||||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
| 2021 | 2020 | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 44,715,743 | $ | 35,300,805 | |||
| Receivable due from collaboration agreement | 831,061 | — | |||||
| Research and development tax incentive receivable | 1,111,540 | — | |||||
| Prepaid assets and other current assets | 833,630 | 2,258,229 | |||||
| Total current assets | 47,491,974 | 37,559,034 | |||||
| Property and equipment, net | 1,810,235 | 1,102,808 | |||||
| Total assets | $ | 49,302,209 | $ | 38,661,842 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,557,612 | $ | 1,297,725 | |||
| Deferred research grant revenue | – | 24,315 | |||||
| Total liabilities | 1,557,613 | 1,322,040 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Common stock | 25,372 | 22,535 | |||||
| Additional paid-in capital | 103,158,144 | 71,648,453 | |||||
| Accumulated other comprehensive loss | (170,328 | ) | (51,538 | ) | |||
| Accumulated deficit | (55,268,591 | ) | (34,279,648 | ) | |||
| Total stockholders’ equity | 47,744,597 | 37,339,802 | |||||
| Total liabilities and stockholders’ equity | $ | 49,302,209 | $ | 38,661,842 | |||
Company Contacts:
gmattes@tffpharma.com
737-802-1973
kcoleman@tffpharma.com
817-989-6358
Investor Relations Contact:
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
269-921-3607
gschanker@lifescicomms.com
1 Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013 May;51(4):361-70. doi: 10.3109/13693786.2012.738312. Epub 2012
Source: TFF Pharmaceuticals, Inc.